Vanderbilt Report Reveals Coeptis’s Funding Breakthrough
Coeptis Therapeutics is formalizing a dual-track operating model that pairs revenue generation with cell therapy development. In Q2 2025,...
Regen BioPharma Announcing Orphan Drug Update at Conference
Regen BioPharma plans to deliver an update on its FDA Orphan Drug Designation application for HemaXellerate in aplastic anemia...
Sensei to Discuss New Data on PD-(L)1 Resistant Tumors
Sensei Biotherapeutics will host a virtual KOL event on October 20, 2025 to outline Phase 2 plans and share...
Seres Advances FDA Talks on SER-155, Cuts Costs for Cash
Seres Therapeutics has secured additional FDA feedback to finalize a Phase 2 protocol for SER-155, an oral live biotherapeutic...
Positive Phase 2a Data for BPL-003 in Resistant Depression
Atai Life Sciences and Beckley Psytech reported positive proof-of-concept data for a two-dose induction regimen of BPL-003, an intranasal...
Scilex’s Semnur, Denali Announce Successful Combination
Semnur Pharmaceuticals has completed its business combination with Denali Capital Acquisition Corp., with the combined entity retaining the Semnur...
Genfit’s Latest H1 2025 Financial Results & Activities
Genfit reported first-half 2025 results alongside a decisive R&D reset: discontinuation of VS-01 in acute-on-chronic liver failure after a...
Synendos Phase 1 Shows Promise for Mental Health Treatment
Synendos Therapeutics reported positive topline results from a Phase 1 program of SYT-510, a first-in-class selective endocannabinoid reuptake inhibitor...
Semnur Signs Startling $100M Stock Deal Funded By Bitcoin
Semnur Pharmaceuticals has entered a securities purchase agreement to raise $100 million through a private placement of 6.25 million...
Biogen Provides Regulatory Update on High-Dose Nusinersen
Biogen received a Complete Response Letter from the FDA for its supplemental filing seeking a higher-dose regimen of nusinersen...